{"id":"valganciclovir-cmv-prophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Renal impairment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Valganciclovir is an L-valyl ester prodrug of ganciclovir that achieves higher oral bioavailability than ganciclovir alone. Once absorbed, it is rapidly converted to ganciclovir, which is phosphorylated by viral kinases and then inhibits CMV DNA polymerase, preventing viral DNA synthesis and replication. This mechanism makes it effective for CMV prophylaxis in immunocompromised patients.","oneSentence":"Valganciclovir is a prodrug that is converted to ganciclovir, which inhibits cytomegalovirus (CMV) DNA polymerase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:32.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"CMV prophylaxis in immunocompromised patients (e.g., post-transplant, HIV-positive)"}]},"trialDetails":[{"nctId":"NCT04439916","phase":"","title":"Breakthrough CMV Lung Transplant -Multicentre","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2021-01-25","conditions":"Cytomegalovirus Infections","enrollment":40},{"nctId":"NCT07430683","phase":"PHASE4","title":"Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Guadalajara","startDate":"2024-03-01","conditions":"Cytomegalovirus Infections","enrollment":68},{"nctId":"NCT05708508","phase":"PHASE3","title":"Effectiveness of an Immune-guided Cytomegalovirus Infection Preventive Strategy Compared to a Universal Prophylactic Strategy in Renal Transplant Patients","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-03-28","conditions":"Kidney Transplant Infection","enrollment":144},{"nctId":"NCT01199562","phase":"","title":"Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2010-12","conditions":"Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia","enrollment":153},{"nctId":"NCT06958796","phase":"PHASE4","title":"Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)","status":"RECRUITING","sponsor":"Camille N. Kotton, MD","startDate":"2025-11-27","conditions":"Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications","enrollment":80},{"nctId":"NCT07294547","phase":"NA","title":"Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-11-27","conditions":"Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis","enrollment":80},{"nctId":"NCT07266467","phase":"PHASE4","title":"Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-05-13","conditions":"Kidney Transplant","enrollment":290},{"nctId":"NCT06034925","phase":"PHASE4","title":"Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"Transplant Complication, CMV","enrollment":70},{"nctId":"NCT06798909","phase":"PHASE3","title":"Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-07-22","conditions":"Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases","enrollment":360},{"nctId":"NCT07203664","phase":"PHASE4","title":"Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitario La Paz","startDate":"2025-10-30","conditions":"Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients","enrollment":30},{"nctId":"NCT07079735","phase":"PHASE2, PHASE3","title":"Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-09-12","conditions":"CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection","enrollment":150},{"nctId":"NCT05708755","phase":"PHASE2","title":"CMV Immunity Monitoring in Lung Transplant Recipients","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-09-13","conditions":"Lung Transplant; Complications","enrollment":50},{"nctId":"NCT05041426","phase":"PHASE2","title":"Letermovir for CMV Prevention After Lung Transplantation","status":"COMPLETED","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2021-12-06","conditions":"Lung Transplant, CMV","enrollment":16},{"nctId":"NCT07009548","phase":"PHASE4","title":"CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2025-06-26","conditions":"Cytomegalovirus (CMV) Infection","enrollment":45},{"nctId":"NCT05238220","phase":"","title":"Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Piedmont Healthcare","startDate":"2021-01-04","conditions":"Kidney Transplant; Complications","enrollment":37},{"nctId":"NCT00227370","phase":"PHASE3","title":"Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-07","conditions":"Cytomegalovirus Infections","enrollment":136},{"nctId":"NCT06057194","phase":"PHASE2","title":"Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2023-10","conditions":"Infections, Cytomegalovirus","enrollment":90},{"nctId":"NCT03699254","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2019-04-05","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":150},{"nctId":"NCT03443869","phase":"PHASE3","title":"Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-05-03","conditions":"CMV Disease","enrollment":601},{"nctId":"NCT01972035","phase":"PHASE2","title":"ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2014-08-01","conditions":"Transplantation Infection, Epstein-Barr Virus Infections, Cytomegalovirus Infections","enrollment":137},{"nctId":"NCT01552369","phase":"PHASE4","title":"CMV Antiviral Prevention Strategies in D+R-Liver Transplants (\"CAPSIL\")","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-10-29","conditions":"Cytomegalovirus Infection","enrollment":205},{"nctId":"NCT02439957","phase":"PHASE3","title":"A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-09","conditions":"Cytomegalovirus Disease, Kidney Transplant Infection","enrollment":6},{"nctId":"NCT02439970","phase":"PHASE3","title":"A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2015-09","conditions":"Cytomegalovirus Disease","enrollment":5},{"nctId":"NCT03339661","phase":"PHASE2","title":"Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2017-11-23","conditions":"Kidney Transplant Infection","enrollment":38},{"nctId":"NCT02538172","phase":"NA","title":"Cell-mediated Immunity for Prevention of CMV Disease","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2015-10","conditions":"Cytomegalovirus Infections","enrollment":195},{"nctId":"NCT03123627","phase":"PHASE3","title":"Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2016-08-23","conditions":"Kidney Transplant Infection","enrollment":150},{"nctId":"NCT04278547","phase":"PHASE4","title":"Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2020-06-12","conditions":"Heart Transplant Infection, CMV Infection","enrollment":188},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00372229","phase":"PHASE3","title":"A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Cytomegalovirus Infections","enrollment":299},{"nctId":"NCT01509404","phase":"PHASE4","title":"Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2011-11","conditions":"Cytomegalovirus Disease","enrollment":40},{"nctId":"NCT01663740","phase":"PHASE4","title":"A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-01-30","conditions":"Cytomegalovirus Infections","enrollment":59},{"nctId":"NCT01335932","phase":"PHASE2","title":"Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-03-10","conditions":"Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure","enrollment":160},{"nctId":"NCT00294515","phase":"PHASE3","title":"IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03-31","conditions":"Cytomegalovirus Infections","enrollment":326},{"nctId":"NCT02370758","phase":"NA","title":"Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-11","conditions":"Cytomegalovirus Viraemia","enrollment":32},{"nctId":"NCT00034385","phase":"PHASE4","title":"Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2002-04-24","conditions":"Kidney Trasplant","enrollment":12},{"nctId":"NCT02973464","phase":"","title":"The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-06","conditions":"Renal Transplant Recipients","enrollment":450},{"nctId":"NCT00141037","phase":"PHASE1, PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"Kidney Diseases, Kidney Transplantation, Kidney Transplant","enrollment":130},{"nctId":"NCT00330018","phase":"PHASE3","title":"Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT)","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2006-02","conditions":"Bone Marrow Transplantation, Cytomegalovirus","enrollment":40},{"nctId":"NCT01446445","phase":"PHASE4","title":"Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.","status":"COMPLETED","sponsor":"Nuria Lloberas","startDate":"2011-12","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":60},{"nctId":"NCT01503918","phase":"PHASE2","title":"Cytomegalovirus Control in Critical Care","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2012-01","conditions":"Critical Illness","enrollment":124},{"nctId":"NCT01049633","phase":"","title":"B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure","status":"NO_LONGER_AVAILABLE","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00275665","phase":"PHASE3","title":"The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2001-11","conditions":"Bone Marrow Stem Cell Transplant","enrollment":20},{"nctId":"NCT00016068","phase":"PHASE3","title":"Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell Transplantation","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2001-01","conditions":"Infection","enrollment":184},{"nctId":"NCT00966836","phase":"PHASE3","title":"Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2009-04","conditions":"Heart Transplantation, Cardiac Allograft Vasculopathy, Cytomegalovirus Infection","enrollment":100},{"nctId":"NCT00225394","phase":"","title":"Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2003-10","conditions":"CMV Disease, Viral Resistance, Rejection","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":204,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valcyte"],"phase":"phase_3","status":"active","brandName":"Valganciclovir CMV Prophylaxis","genericName":"Valganciclovir CMV Prophylaxis","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valganciclovir is a prodrug that is converted to ganciclovir, which inhibits cytomegalovirus (CMV) DNA polymerase to prevent viral replication. Used for CMV prophylaxis in immunocompromised patients (e.g., post-transplant, HIV-positive).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}